Here's Why You Should Retain Adient Stock in Your Portfolio Now
ADNT raises 2026 guidance as customer production, new business wins and share repurchases support growth despite Europe and China pressures.
ADNT - Adient plc
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$28.67
DETAILS
HIGH:
$33.00
LOW:
$22.00
MEDIAN:
$29.00
CONSENSUS:
$28.67
UPSIDE:
32.85%
Stock News
Here's Why Adient (ADNT) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Compared to Estimates, Adient (ADNT) Q2 Earnings: A Look at Key Metrics
The headline numbers for Adient (ADNT) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Adient: Bullish On The 'Beat And Raise'
I retain a 'buy' rating for Adient plc following my assessment of its performance and prospects. ADNT's revenue growth acceleration and 18% EPS beat for 2Q FY2026 were driven by Chinese OEM penetration and good cost control. Its updated FY2026 guidance already suggests a likely improvement over FY25. Further upside is possible, assuming that the new products deliver the desired synergies.
Adient plc (ADNT) Q2 2026 Earnings Call Transcript
Adient plc (ADNT) Q2 2026 Earnings Call Transcript
ADNT Q2 Earnings Beat on Revenue Growth and Solid Execution
Adient beat Q2 earnings estimates as sales rose 7%, despite margin pressure. It also lifted FY2026 guidance.
Adient (ADNT) Beats Q2 Earnings and Revenue Estimates
Adient (ADNT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.69 per share a year ago.
Adient reports second quarter financial results
PLYMOUTH, Mich., May 6, 2026 /PRNewswire/ -- Adient (NYSE: ADNT), a global leader in automotive seating, today announced its second quarter 2026 financial results.
3 Cyclical Stocks to Buy For A Potential Summer Recovery
It's been a challenging year for cyclical stocks on Wall Street as geopolitical uncertainty has severely disrupted consumer confidence, but the prospect of a brightening economic outlook in the US could drive these four cyclical stocks higher moving into the summer months.
Analysts Estimate Adient (ADNT) to Report a Decline in Earnings: What to Look Out for
Adient (ADNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adient acquires automotive seating foam plant in Romulus, MI
PLYMOUTH, Mich., April 27, 2026 /PRNewswire/ -- Adient (NYSE: ADNT), a global leader in automotive seating, today announced that it has expanded its operational footprint by acquiring a foam production plant in Romulus, MI.
Adient Introduces ProForce Massage Flow Solution
PLYMOUTH, Mich., April 24, 2026 /PRNewswire/ -- Adient (NYSE: ADNT), a global leader in automotive seating, is advancing its mechanical massage portfolio with the commercialization of the ProForce Massage Flow solution.
Adient launches StepJoy foot massage innovation
PLYMOUTH, Mich., April 10, 2026 /PRNewswire/ -- As consumer expectations for in‑vehicle comfort continue to rise, Adient (NYSE: ADNT), a global leader in automotive seating, is expanding its massage offerings with the launch of StepJoy, its latest foot massage innovation.
Adient to discuss Q2 fiscal 2026 financial results on May 6, 2026
PLYMOUTH, Mich., April 7, 2026 /PRNewswire/ -- Adient (NYSE: ADNT), a global leader in automotive seating, will host a conference call on May 6, 2026, at 8:30 a.m.
Why Adient (ADNT) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Adient (ADNT) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Adient (NYSE:ADNT) Receives Consensus Recommendation of “Hold” from Analysts
Adient (NYSE: ADNT - Get Free Report) has been given a consensus recommendation of "Hold" by the twelve research firms that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating on the company. The average twelve-month
Adient (ADNT) Down 12.6% Since Last Earnings Report: Can It Rebound?
Adient (ADNT) reported earnings 30 days ago. What's next for the stock?
Here's Why Adient (ADNT) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Counterpoint Mutual Funds LLC Sells 22,424 Shares of Adient $ADNT
Counterpoint Mutual Funds LLC lowered its holdings in Adient (NYSE: ADNT) by 51.9% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,755 shares of the company's stock after selling 22,424 shares during the period. Counterpoint Mutual Funds LLC's holdings
Price Targets
Adient price target raised to $29 from $26 at Barclays
$29.00
(was $22.78)
Barclays
Adient price target raised to $31 from $30 at Deutsche Bank
$31.00
(was $22.35)
Deutsche Bank
Adient price target raised to $33 from $32 at UBS
$33.00
(was $22.32)
UBS
Adient price target raised to $28 from $26 at Stifel
$28.00
(was $22.32)
Nathan Jones
·
Stifel Nicolaus
Adient price target raised to $22 from $20 at Morgan Stanley
$22.00
(was $24.26)
Morgan Stanley
Adient price target raised to $32 from $30 at UBS
$32.00
(was $24.26)
UBS
Adient price target raised to $26 from $24 at Stifel
$26.00
(was $21.79)
Stifel Nicolaus
Adient price target raised to $25 from $24 at Barclays
$25.00
(was $21.85)
Barclays
Adient upgraded to Buy from Neutral at UBS
$30.00
(was $21.45)
UBS
Adient price target raised to $29 from $28 at Wells Fargo
$29.00
(was $20.60)
Colin Langan
·
Wells Fargo
Adient price target raised to $29 from $27 at Stifel
$29.00
(was $22.82)
Stifel Nicolaus
Adient price target raised to $27 from $25 at Barclays
$27.00
(was $23.39)
Barclays
Adient price target raised to $28 from $26 at UBS
$28.00
(was $25.89)
UBS
Adient upgraded to Overweight from Equal Weight at Wells Fargo
$31.00
(was $24.71)
Wells Fargo
Adient price target lowered to $17 from $19 at Morgan Stanley
$17.00
(was $14.74)
Morgan Stanley
Adient upgraded to Neutral from Underperform at Exane BNP Paribas
$26.00
(was $24.71)
James Picariello
·
BNP Paribas
Adient price target lowered to $34 from $37 at Barclays
$34.00
(was $28.12)
Dan Levy
·
Barclays
Adient (ADNT) PT Lowered to $30 at Deutsche Bank
$30.00
(was $27.41)
Emmanuel Rosner
·
Deutsche Bank
Adient (ADNT) PT Lowered to $33 at Deutsche Bank Post Mgmt Meeting
$33.00
(was $32.92)
Emmanuel Rosner
·
Deutsche Bank
Adient (ADNT) Stock Price: $31 Target From Morgan Stanley
$31.00
(was $34.38)
Adam Jonas
·
Morgan Stanley